Credit Suisse
Credit Suisse Group operates as a financial services company. The company operates in three segments: Investment Banking, Private Banking, and Asset Management.
The Investment Banking segment supplies investment banking and securities products and services to corporate, institutional, and government clients worldwide.
The Private Banking segment offers investment advice; wealth management solutions, including pension planning, life insurance products, and tax and wealth planning; and inheritance advice, which is tailored to the needs of high-net-worth individuals.
The Asset Management segment supplies products from the investment classes, such as money market, fixed-income, equities, balanced, and alternative investments to meet the needs of institutional, government, and private clients worldwide.
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) 77% LOWER; today announced that its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer did not meet its primary endpoint of overall survival. The analysis, based on 320 evaluable events (patient deaths), showed a hazard ratio of 0.82 with a p value of 0.089. The stock was also downgraded at Merriman Curhan Ford.
Spherix Incorporated (NASDAQ: SPEX) 72% HIGHER; today announced positive interim Phase 3 clinical results for the planned review of the NEET (Naturlose (D-tagatose) Efficacy Evaluation Trial) trial of D-tagatose in drug naive patients. Click here to see the full report.
CombinatoRx, Incorporated (NASDAQ: CRXX) 39.3% LOWER; CRXX and Neuromed Pharmaceuticals Inc. today announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application for the product candidate EXALGO^TM (hydromorphone HCl extended release) ...
